High On Drugs? Anthem Cites Soaring Drug Costs To Justify 35% Rate Hike in California
The company’s drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
Drugs
1,101-1,120 of 1,312 results
-
-
The Orphan Drug Machine
Without Price Breaks, Rural Hospitals Struggle To Stock Costly, Lifesaving Drugs
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
-
The Orphan Drug Machine
FDA Moves To Guard Against Abuse Of ‘Orphan Drug’ Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
-
Meningitis B Vaccine’s High Price Poses A Health Care Conundrum For College-Bound
This immunization may mark a shift among some vaccine makers to higher-priced, “niche” preventives that protect against very specific and sometimes rare illnesses.
-
St. Kitts Launches Probe Of Herpes Vaccine Tests On U.S. Patients
After a Kaiser Health News report on an offshore herpes vaccine trial that skirted FDA regulations, St. Kitts and Nevis officials claim they had no knowledge of the testing. An investigation is underway.
-
Pioneering Cancer Gene Therapy Gets Green Light — And $475,000 Price Tag
The USA's first approved gene therapy — to be used to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment.
By Liz Szabo -
Facebook Live: The Prescription Drug Pricing Pipeline
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
-
Offshore Human Testing Of Herpes Vaccine Stokes Debate Over U.S. Safety Rules
Prominent businessmen and an American university supported offshore testing of an experimental vaccine.
-
‘Breakthrough’ Leukemia Drug Also Portends ‘Quantum Leap’ In Cost
A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.
By Liz Szabo -
Dying At Home In An Opioid Crisis: Hospices Grapple With Stolen Meds
As more patients receive hospice care at home, some of the powerful, addictive drugs they’re prescribed are ending up in the wrong hands.
-
Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?
In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
-
Climbing Cost Of Decades-Old Drugs Threatens To Break Medicaid Bank
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
-
Hospitals Slashed Use Of Two Heart Drugs After Huge Price Hikes
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
-
Taking A U-Turn On Benefits, Big Employers Vow To Continue Offering Health Insurance
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
By Jay Hancock -
To Grow Market Share, A Drugmaker Pitches Its Product To Judges
Some drug courts offer participants a full range of evidence-based treatment, including medication-assisted treatment. Others don't allow addiction medications at all. And some permit just one: Vivitrol.
-
Florida Law Will Let Patients Get All Their Drug Renewals At The Same Time
The new law will help people with chronic conditions that require multiple prescriptions cut down on their shuttles to the drug store and could improve adherence to their drugs.
-
Denial, Appeal, Approval … An Adult’s Thorny Path To Spinraza Coverage
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
-
Drug Puts A $750,000 ‘Price Tag On Life’
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
-
Follow The Money: Drugmakers Deploy Political Cash As Prices And Anger Mount
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
-
Congress Squares Off Over Drug Pricing And A Controversial Drug Discount Program
The controversial 340B drug discount program for hospitals came under fire at a congressional hearing.